Introduction
Melanotan 2 (MT-II) is a cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH), studied as a non-selective agonist of the melanocortin-receptor family. Developed from structure–activity research on α-MSH at the University of Arizona, MT-II is notable for its metabolic stability — the cyclic structure resists the rapid degradation that limits the native hormone — and for the breadth of its receptor engagement across the melanocortin system. In research contexts it serves as a reference tool for studying melanocortin-receptor pharmacology and the biochemistry of melanogenesis. This article surveys what the peer-reviewed literature describes about its mechanism, the discovery research that characterized it, its place among melanocortin ligands, and how research-grade material is handled. Everything is framed strictly for laboratory research use only; the discussion is confined to receptor pharmacology and biochemistry in model systems. The findings are not human outcomes, and nothing here describes, recommends, or implies any human use.Mechanism of Action
MT-II acts on the melanocortin receptors, a family of five G-protein-coupled receptors (MC1R through MC5R) with distinct tissue distributions and signaling roles. As a non-selective agonist, MT-II engages multiple members of this family rather than a single subtype. In research models, its activity is described across MC1R (associated with melanogenesis biochemistry), MC3R and MC4R (associated with central energy-balance and signaling pathways), and MC5R (associated with exocrine and peripheral signaling) (Hadley et al., 1981). The structural basis for MT-II's usefulness as a research tool is its cyclic conformation. Native α-MSH is rapidly degraded, limiting its experimental utility; the cyclization in MT-II confers metabolic stability and prolonged activity, making it a more tractable reagent for studying melanocortin-receptor signaling and melanogenesis biochemistry (Dorr et al., 1996).Mechanism of Action — Deep Dive
The melanocortin-receptor family. The five melanocortin receptors are a textbook example of a receptor family in which a shared ligand class produces divergent effects depending on which subtype and tissue is engaged. MT-II's non-selectivity makes it a tool for studying the family as a whole, while contrasting it with subtype-selective ligands isolates individual receptor contributions (Hadley et al., 1981). Stability through cyclization. The defining engineering feature of MT-II is its cyclic structure. By constraining the peptide conformation, cyclization both stabilizes the molecule against enzymatic degradation and can enhance receptor engagement relative to the linear native hormone — a recurring theme in peptide-analog design and the reason MT-II became a durable research reagent (Dorr et al., 1996). Relationship to selective analogs. MT-II is the parent structure from which more selective melanocortin ligands were derived. Notably, the selective MC4R agonist bremelanotide (PT-141) was developed from MT-II. This lineage makes MT-II a useful reference point in melanocortin medicinal-chemistry research, illustrating how selectivity can be engineered from a non-selective scaffold.Key Research Findings
The findings below are model-system observations from the peer-reviewed literature — confined to receptor pharmacology and biochemistry, not human outcomes, and not human-use guidance.Finding 1 — A metabolically stable α-MSH analog
Type of evidence: structure–activity discovery research (Hadley et al., 1981). Finding: the cyclic [Nle⁴, D-Phe⁷] modification produced a metabolically stable α-MSH analog with prolonged melanogenic activity in research models. Why it matters: it established MT-II as a stable reference ligand for melanocortin research (Hadley et al., 1981).Finding 2 — Non-selective melanocortin-receptor agonism
Type of evidence: pharmacology characterization (Dorr et al., 1996, and subsequent receptor studies). Finding: MT-II engages multiple melanocortin-receptor subtypes (MC1R, MC3R, MC4R, MC5R) rather than a single target. Why it matters: it defines MT-II's role as a whole-family research probe and the scaffold from which selective analogs were derived (Dorr et al., 1996).Related Compounds Comparison Table
| Molecule | Selectivity | Receptor focus | Relationship to MT-II |
|---|---|---|---|
| Melanotan 2 (MT-II) | Non-selective | MC1R–MC5R | The reference scaffold |
| PT-141 (bremelanotide) | MC4R-selective | MC4R | Derived from MT-II |
| α-MSH (native) | Endogenous ligand | Melanocortin family | The parent hormone MT-II is modeled on |
| KPV | Non-receptor | (α-MSH C-terminus) | α-MSH fragment without receptor binding |
Research Applications
Within laboratory settings, research-grade MT-II is studied in melanocortin-receptor pharmacology, melanogenesis biochemistry, and α-MSH-analog medicinal-chemistry research. It functions as a defined non-selective reference ligand against which subtype-selective compounds can be compared to attribute effects to specific receptors. Researchers commonly pair MT-II studies with receptor-binding assays and cyclic-AMP signaling readouts across the melanocortin-receptor subtypes. Across all designs, MT-II serves as a tool for interrogating melanocortin-receptor biology, never as a product for application outside the laboratory.Storage & Handling Protocols for Research Use
Research-grade MT-II is typically supplied as a lyophilized peptide powder, chosen because dry material is far more stable than material in solution. The considerations below are general laboratory-storage practice, not instructions for any human use. Dry powder is commonly stored at −20 °C or colder (often −80 °C for archival material), protected from moisture by desiccant and shielded from light. Because the powder is hygroscopic, laboratories equilibrate a sealed vial to room temperature before opening. Material in solution is prone to degradation, with stability sensitive to pH, temperature, and freeze–thaw cycling, so many groups prepare small single-use aliquots. Because no generic shelf life can be assumed, research groups validate stability empirically. VOREX does not provide reconstitution recipes, concentrations, or use protocols; those decisions sit with the qualified researcher.Laboratory Handling & Best Practices
Record the vial's lot number against every experiment, with working aliquots inheriting it.Use clean glassware and PPE, document storage history and freeze–thaw count, and weigh small quantities on a calibrated analytical balance, accounting for the hygroscopic tendency of lyophilized powders. None of these practices involves dosing, route of administration, or human-use preparation; they exist to protect data integrity and reproducibility.What the Research Doesn't Tell Us
The literature is candid about its limits. As a non-selective agonist, MT-II engages multiple receptor subtypes simultaneously, so attributing a given readout to a single receptor requires subtype-selective comparators. Much of the characterization derives from defined experimental contexts and model systems, and results may not generalize across systems. The biochemistry of melanocortin signaling continues to be mapped. For the researcher, MT-II is best approached as a broad melanocortin-receptor probe whose non-selectivity is both its utility and its interpretive challenge.Conclusion
MT-II research describes a metabolically stable, cyclic α-MSH analog that acts as a non-selective melanocortin-receptor agonist — a durable reference scaffold for melanocortin-receptor pharmacology and the structure from which selective analogs were engineered. It is a mechanism worth measuring rather than a claim worth selling, and for laboratories working on melanocortin biology it remains a valuable reference material. View research data · Request COA · Explore mechanism studiesReferences
- Hadley, M.E., Anderson, B., Heward, C.B., Sawyer, T.K., & Hruby, V.J. (1981). Calcium-dependent prolonged effects on melanophores of [4-norleucine, 7-D-phenylalanine]-α-melanotropin. Science, 213(4514), 1289–1290. https://pubmed.ncbi.nlm.nih.gov/7268417/
- Dorr, R.T., Lines, R., Levine, N., Brooks, C., Xiang, L., Hruby, V.J., & Hadley, M.E. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 58(20), 1777–1784. https://pubmed.ncbi.nlm.nih.gov/8637402/
For laboratory and research use only (RUO). Not for human consumption, diagnostic, or therapeutic use. VOREX products are intended exclusively for in vitro research conducted by qualified professionals. Statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.
